Date of investment
Oxford Biomedica is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.
Departments: Growth Investments, Novo Holdings Equity US Inc., Life Sciences Operating Committee
Robert joined Novo Holdings in January 2018 and serves as a Managing partner and head of Growth Investments.
Before joining Novo Holdings, Robert was a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the Healthcare Industry. Prior to Moelis, Robert was part of the UK Mergers & Acquisitions team at Deutsche Bank in London.
Robert holds a J.Hons. B.A. degree in Finance and Economics from McGill University and a M.Sc. degree in Financial Economics from the University of Oxford.